Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 56-66

  Albanell, Joan ^a   Rojo, Federico ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BIOPSY; BREAST ADENOCARCINOMA; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; TOXICITY;

EID: 0035174127     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28551     Document Type: Conference Paper

References (53)

1. Growth factors and cancer
2. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors
3. Regulation of signal transduction and signal diversity by receptor oligomerization
4. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
5. Expression in rat fibroblasts of a human transforming growth factoralpha cDNA results in transformation
6. Autocrine interaction between TGF alpha and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype
7. Epidermal growth factor-related peptides and their receptors in human malignancies
8. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer
9. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
10. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
11. The ErbB receptors as targets for breast cancer therapy
12. Monoclonal antibodies directed against growth factor receptors
13. ZD1839 (Iressa) as an anticancer agent
14. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
15. ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
16. The epidermal growth factor receptor and its inhibition in cancer therapy
17. 6-amino4(3-methyl-phenylamino)-quinazoline: An EGF receptor tyrosine kinase inhibitor with activity in a range of human turnout xenografts
18. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
19. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
20. Signal transduction through MAP kinase cascades
21. A family of proteins that inhibit signalling through tyrosine kinase receptors
22. Activated epidermal growth factor receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tyrosine-kinase inhibitors
23. Pharmacodynamic effects of Iressa, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in skin biopsies from patients participating in a phase I trial
24. Blockade of the EGF receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGFα bigenic mice
25. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
26. New insights into tumor suppression PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
27. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development
28. KiP1 independent of MAPK activity
29. Kip1 inducing G1 arrest and enhancing the antitumor effect of interferon α
30. EGFR tyrosine kinase inhibition decreases epithelial proliferation in DC1S of the breast, whereas c-erbB2 blockade does not
31. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents
32. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
33. Activation of mitogen-activated protein kinase is associated with epidermal growth factor receptor, transforming growth factor alpha and HER2 receptor overexpression in head and neck tumors
34. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis
35. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis
36. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma
37. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma
38. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
39. Activation of mitogen-activated protein kinase associated with prostate cancer progression
40. In situ visualization of intratumor growth factor signaling: Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms
41. Biological and clinical associations of c-jun activation in human breast cancer
42. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage
43. Monoclonial against recombibnant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwaveprocessed formalin-fixed paraffin sections
44. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
45. Production and auto-induction of transforming growth factor-alpha in human keratinocytes
46. Strain-dependent epithelial defects in mice lacking the EGF receptor
47. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
48. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure
49. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
50. New therapeutic agents targeting the epidermal growth factor receptor J Clin Oncol
51. Pharmacodynamic effects of the EGF receptor inhibitor ZD1839 (Iressa) in skin from cancer patients: Histopathological and molecular consequences of receptor inhibition
52. STAT3 activation accompanies keratinocyte differentiation
53. Epidermal growth factor/transforming growth factor alpha receptors and psoriasis